Evaluation Of The Efficacy And Safety Of Tribulus Terrestris In Male Sexual Dysfunction-A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial
Notes for this study:
||(nmol/L) SHBG was 31.34 at baseline and 33.95 after 12 weeks in the intervention group and 35.20 at baseline and 35.41 after 12 weeks in the placebo group
|Number of Subjects
||18-29, 30-44, 45-64
180 men with erectile dysfunction took 1.5 g/d of Tribulus (divided into 3 equal doses) or placebo for 12 weeks. IIEF score, the primary outcome, improved significantly more in the intervention group than the placebo group at 4, 8, and 12 weeks. A significantly higher percentage of participants in the intervention group reported improved erections. There was no significant difference between the groups for levels of testosterone, free testosterone, DHEA-S or SHBG. Total cholesterol, LDL-C, HDL-C, triglycerides, and blood pressure were unchanged.
Funding issues for this study:
The authors note that: "The study was funded by Sopharma AD, the manufacturer of Tribestan. The data were analysed and interpreted by an independent statistician. Data were recorded at participating clinical centers. All authors had full access to the data. The authors had final responsibility for the decision to submit for publication"
Multiple authors have financial ties to Sopharma AD.